Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. - Wikidata - awgldk - TriplyDB

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.

http://www.wikidata.org/entity/Q37600183

about

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab.Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group.Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration.Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis.Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab.Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance.

P2860

Q33596886-7CD6711D-20A2-4E7D-8318-F23B0F11F7DE Q36407317-D3EEBC79-165D-4DFC-BF06-9E27D5293A2B Q37143095-A4F0DC28-8ADF-4693-848D-28A3F02F5536 Q37582768-CF91D68D-7D0A-4A49-BC0A-2A152B919129 Q37714528-16FBA70B-F2F5-4E74-B883-69BEF515AE2E Q52595306-A19CE87E-38E6-451B-91A1-D2C0CDFFFD50

P2860

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.

http://www.wikidata.org/entity/Q37600183

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of switching from rani ...... -related macular degeneration.

@en

Effects of switching from rani ...... -related macular degeneration.

@nl

type

label

Effects of switching from rani ...... -related macular degeneration.

@en

Effects of switching from rani ...... -related macular degeneration.

@nl

prefLabel

Effects of switching from rani ...... -related macular degeneration.

@en

Effects of switching from rani ...... -related macular degeneration.

@nl

P1433

Q37600183-5093D903-8D4B-429D-A29C-AA45F6A5BD1F

P1476

Q37600183-557471E1-7204-42CB-BFEA-5E1E6823ED08

P2093

Q37600183-1AC12638-842B-4394-B48D-8C81C724E138

Q37600183-20E8EC20-D6DD-4D13-9E5F-394E6FC1988C

Q37600183-3571740F-FDE8-4C45-89EB-9309F1580F6F

Q37600183-38A0DF14-6618-4ECF-863A-E24016F50C6E

Q37600183-4096B72B-EC32-4C54-A48D-59D2C6B8575A

Q37600183-4338107F-7D0B-40BC-AAAE-487B1CC31F96

Q37600183-4B844C5C-74B1-4C80-94AE-219195C61361

Q37600183-784C40D8-5A61-40BE-9B68-4556B35637E9

Q37600183-9F86BAC8-1E02-41F9-B32F-49EE61F20C0B

Q37600183-C147464D-AB2E-4055-83AE-865EBD40EE7A

P2860

Q37600183-115FD0C4-C6A7-4DDE-9492-58286CBB0369

Q37600183-18D48EDE-2EC2-4AD6-A972-E5CC9A6A5197

Q37600183-24F6CDD2-597B-4BE5-BBE0-D0739F940D07

Q37600183-39C1CE56-E799-4D54-A1C9-A193A7A27F8E

Q37600183-4D625EB8-BF56-45C8-8B22-627F34C7FED3

Q37600183-4FD214B4-8842-4CB4-A53B-4ABCCE193D3A

Q37600183-52A893A6-EA97-4141-A0FB-8CCA2F827421

Q37600183-569DA6FC-91FA-4F76-B0D6-7447BBC68436

Q37600183-5DA38D6E-2B35-41AF-BFF8-FD9563AD8012

Q37600183-6075CCD6-DC9A-47F7-BFC8-FD9F14A1DD57

P304

Q37600183-896E13F3-824D-4DDD-AA59-1ED1E0CDDFAD

P31

Q37600183-97D47A1B-C497-472C-8205-9383C7C6040C

P356

Q37600183-4FACB690-12CD-4D59-82FA-AEFDC67285B4

P407

Q37600183-D5E047F3-8C70-410D-8951-6E1E7A48B0BA

P433

Q37600183-060BA8CF-625D-4A78-8DDD-39C67144A07E

P478

Q37600183-0ED1AA0A-524F-4C5A-BFB3-EAD4FB6CC93C

P50

Q37600183-3A883FB5-5DBE-434F-9AFE-7E0C07AB7469

Q37600183-AA0EE641-6AB4-4570-9BF2-A4AF8A16BC44

P577

Q37600183-463240D5-B908-40CD-9DC0-22FBFFBF5A95

P698

Q37600183-CEA82FB5-F763-4D26-8686-D19DCBA5246F

P932

Q37600183-8B346401-30A4-4E3D-BBD5-2ED778A98E90

P356

BJOPHTHALMOL-2015-308090

P1433

British Journal of Ophthalmology

P1476

Effects of switching from rani ...... e-related macular degeneration

@en

P2093

Alex P Hunyor

http://www.w3.org/2001/XMLSchema#string

Anna Campain

http://www.w3.org/2001/XMLSchema#string

Daniel Barthelmes

http://www.w3.org/2001/XMLSchema#string

Fight Retinal Blindness! Project Investigators

http://www.w3.org/2001/XMLSchema#string

Ian L McAllister

http://www.w3.org/2001/XMLSchema#string

Jennifer J Arnold

http://www.w3.org/2001/XMLSchema#string

Judy M Simpson

http://www.w3.org/2001/XMLSchema#string

Mark C Gillies

http://www.w3.org/2001/XMLSchema#string

Nigel Morlet

http://www.w3.org/2001/XMLSchema#string

Phuc Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Ranibizumab for neovascular age-related macular degeneration

Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project.

Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.

Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration.

P304

1640-1645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BJOPHTHALMOL-2015-308090

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Robyn H. Guymer

P577

2016-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26994110

http://www.w3.org/2001/XMLSchema#string

P932

5256411

http://www.w3.org/2001/XMLSchema#string